Form 8-K - Current report:
SEC Accession No. 0001829126-25-002284
Filing Date
2025-04-01
Accepted
2025-04-01 16:05:24
Documents
16
Period of Report
2025-03-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 48057
2 EXHIBIT 4.1 titanpharma_ex4-1.htm EX-4.1 107962
3 EXHIBIT 10.1 titanpharma_ex10-1.htm EX-10.1 240943
4 EXHIBIT 10.2 titanpharma_ex10-2.htm EX-10.2 90655
  Complete submission text file 0001829126-25-002284.txt   755352

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ttnp-20250326.xsd EX-101.SCH 2990
6 XBRL LABEL FILE ttnp-20250326_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE ttnp-20250326_pre.xml EX-101.PRE 22342
18 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3688
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 25799606
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)